Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00453609 · ClinicalTrials.gov registry record · Phase 4
Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)
A Phase 4 study, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00453609 is a Phase 4 study that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 15 participants.
The verdict
NCT00453609, a Phase 4 study, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The overall goal of this project is to improve the treatment of alcohol dependence in patients with serious mental illness (SMI). SMI for this study is defined as any patient with any of the following diagnoses: schizophrenia, schizoaffective disorder, and bipolar type I or type II disorder. Alcohol and other substance use disorders (SUDs) are common among individuals with SMI. SUD comorbidity is associated with many adverse consequences. However, to date, few reports have addressed the efficacy of pharmacological treatments for SUDs in this population. Naltrexone pharmacotherapy is an effective treatment for alcohol dependence, but it has not been systematically applied to the care of patients with SMI. The primary aim of this study is to determine the feasibility of long-acting injectable naltrexone administration in a clinical trial in patients with SMI who also have a diagnosis of alcohol dependence. Secondary aims include providing a preliminary assessment of the tolerability and safety of long-acting injectable naltrexone in patients with SMI who also have a diagnosis of alcohol dependence. An additional aim is to provide a preliminary assessment of the efficacy of long-acting injectable naltrexone in reducing alcohol use from baseline levels.
Interventions
- DRUG long-lasting injectable naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00453609
The ClinicalTrials.gov registry entry for NCT00453609 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which long-lasting injectable naltrexone is the first listed.
NCT00453609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00453609 about?
NCT00453609 is a clinical study titled "Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)". The overall goal of this project is to improve the treatment of alcohol dependence in patients with serious mental illness (SMI). SMI for this study is defined as any patient with any of the following diagnoses: schizophrenia, schizoaffective disorder, and bipolar type I or type II disorder. Alcohol...
What is the current status of trial NCT00453609?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2007-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00453609?
The interventions under investigation include: long-lasting injectable naltrexone (DRUG).
Who is sponsoring clinical trial NCT00453609?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.